Catalyst Pharmaceutical Partners, Inc. announced today positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 is bioavailable and bioequivalent to Sabril® Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis.
From: biz.yahoo.com
Wednesday, May 9, 2007
Vigabatrin), ...
Subscribe to:
Post Comments (Atom)
![Digitalpoint Geo Tracking [Enabled]](http://geo.digitalpoint.com/a.png)
![PingOmatic AutoDiscovery [Enabled]](http://www.genuineblogger.com/images/chicklet-pingomatic.gif)
![Made with Palestinian Efforts [True]](http://www.genuineblogger.com/images/yapalestinets.gif)
No comments:
Post a Comment